Your browser doesn't support javascript.
loading
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies.
Hegde, Aparna; Andreev-Drakhlin, Alexander Y; Roszik, Jason; Huang, Le; Liu, Shuang; Hess, Kenneth; Cabanillas, Maria; Hu, Mimi I; Busaidy, Naifa L; Sherman, Steven I; Dadu, Ramona; Grubbs, Elizabeth G; Ali, Siraj M; Lee, Jessica; Elamin, Yasir Y; Simon, George R; Blumenschein, George R; Papadimitrakopoulou, Vassiliki A; Hong, David; Meric-Bernstam, Funda; Heymach, John; Subbiah, Vivek.
Afiliación
  • Hegde A; Department of Hematology Oncology, The University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Andreev-Drakhlin AY; Department of Hematology Oncology, UTMDACC, Houston, Texas, USA.
  • Roszik J; Department of Melanoma Medical Oncology, UTMDACC, Houston, Texas, USA.
  • Huang L; Department of Investigational Cancer Therapeutics, UTMDACC, Houston, Texas, USA.
  • Liu S; Department of Investigational Cancer Therapeutics, UTMDACC, Houston, Texas, USA.
  • Hess K; Department of Biostatistics, UTMDACC, Houston, Texas, USA.
  • Cabanillas M; Department of Endocrine Neoplasia and Hormonal Disorders, UTMDACC, Houston, Texas, USA.
  • Hu MI; Department of Endocrine Neoplasia and Hormonal Disorders, UTMDACC, Houston, Texas, USA.
  • Busaidy NL; Department of Endocrine Neoplasia and Hormonal Disorders, UTMDACC, Houston, Texas, USA.
  • Sherman SI; Department of Endocrine Neoplasia and Hormonal Disorders, UTMDACC, Houston, Texas, USA.
  • Dadu R; Department of Endocrine Neoplasia and Hormonal Disorders, UTMDACC, Houston, Texas, USA.
  • Grubbs EG; Department of Surgical Oncology, UTMDACC, Houston, Texas, USA.
  • Ali SM; Department of Clinical Development, Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Lee J; Department of Clinical Development, Foundation Medicine Inc, Cambridge, Massachusetts, USA.
  • Elamin YY; Department of Thoracic Head and Neck Medical Oncology, UTMDACC, Houston, Texas, USA.
  • Simon GR; Department of Thoracic Head and Neck Medical Oncology, UTMDACC, Houston, Texas, USA.
  • Blumenschein GR; Department of Thoracic Head and Neck Medical Oncology, UTMDACC, Houston, Texas, USA.
  • Papadimitrakopoulou VA; Department of Thoracic Head and Neck Medical Oncology, UTMDACC, Houston, Texas, USA.
  • Hong D; Department of Investigational Cancer Therapeutics, UTMDACC, Houston, Texas, USA.
  • Meric-Bernstam F; Department of Investigational Cancer Therapeutics, UTMDACC, Houston, Texas, USA.
  • Heymach J; Department of Thoracic Head and Neck Medical Oncology, UTMDACC, Houston, Texas, USA.
  • Subbiah V; Department of Investigational Cancer Therapeutics, UTMDACC, Houston, Texas, USA. Electronic address: vsubbiah@mdanderson.org.
ESMO Open ; 5(5): e000799, 2020 10.
Article en En | MEDLINE | ID: mdl-33097651
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: ESMO Open Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Tiroides / Inhibidores de Puntos de Control Inmunológico Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: ESMO Open Año: 2020 Tipo del documento: Article